IL-17A plays a role in SpA manifestations related to the skin, joints and enthesis, as reflected by the suppression of disease activity seen with IL-17A inhibitors in psoriasis, PsA and AS [42,43,44,45,46,47,48,49]. Here, IL17A is linked to psoriasis.